Printer Friendly

Ono Pharmaceutical, Dainippon Sumitomo Pharma to Enter into Joint Development and Marketing Agreement for Limaprost Alfadex, Oral PGE1 Derivative.

Tokyo, Japan, Dec 6, 2005 - (JCN) - Ono Pharmaceutical and Dainipopn Sumitomo Pharma jointly announced on December 6 that they have singed a joint development and marketing agreement for limaprost alfadex, an oral prostaglandin E1 derivative indicated for the treatment of peripheral circulatory disturbance.

Under the agreement terms, the two companies aim to obtain approval for an additional indication of limaprost alfadex, namely the treatment of cervical spondylosis.

Currently, limaprost alfadex is marketed by the two companies: OPALMON Tablet by Ono Pharmaceutical and PRORENAL Tablet by Dainippon Sumitomo.

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Dec 8, 2005
Previous Article:Nippon Sheet Glass, Kagome and Kajima to Jointly Develop Large-scale Energy-saving Greenhouse for Tomato Cultivation.
Next Article:Hosokawa Powder Technology Research Institute to Construct New Functional Nanocomposite Manufacturing Plant in Nara.

Related Articles
Dainippon Sumitomo Pharma Kicks off Operations.
Sumitomo Chemical Files Suit Against Pfizer for Amlodipine Besilate.
Dainippon Sumitomo Pharma and Eisai Sign Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members.
Dainippon Sumitomo Pharma Announces Results of Clinical Trial of Mosapride Citrate.
Dainippon Sumitomo Pharma Licenses Precursor of Norepinephrine to Chelsea Therapeutics International.
Dainippon Sumitomo Pharma Enters into Partnership Agreement on Anti-Hypertension and Hepatocellular Cancer Drugs.
Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'.
Sumitomo Chemical Reports Interim Consolidated Financial Results.
Dainippon Sumitomo Pharma Announces Launch of "Replagal(R) 3.5 mg" for Anderson-Fabry Disease.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters